Antibacterial activities of iron chelators against common nosocomial pathogens

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5419-5421

  Thompson, Mitchell G ^a   Corey, Brendan W ^a   Si, Yuanzheng ^a,b   Craft, David W ^a,b   Zurawski, Daniel V ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APO 6619; DEFERIPRONE; DEFEROXAMINE MESYLATE; IRON CHELATING AGENT; TISSUE CULTURE MEDIUM; UNCLASSIFIED DRUG; VK 28;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; ESCHERICHIA COLI; GROWTH INHIBITION; HOSPITAL INFECTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; DEFEROXAMINE; IRON CHELATING AGENTS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PYRIDONES; STAPHYLOCOCCUS AUREUS;

EID: 84866334623     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01197-12     Document Type: Article

References (28)

1. Boucher HW, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
2. Brown TS, Hawksworth JS, Sheppard FR, Tadaki DK, Elster E. 2011. Inflammatory response is associated with critical colonization in combat wounds. Surg. Infect. 12:351-357.
3. Chakrabarty P, et al. 2011. Iron chelation therapy and thalassemia: an overview. Mymensingh Med. J. 20:513-519.
4. Chan GC, Chan S, Ho PL, Ha SY. 2009. Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin 33:352-360.
5. CLSI. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement, p 152. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Collins HL, Kaufmann SH, Schaible UE. 2002. Iron chelation via deferoxamine exacerbates experimental salmonellosis via inhibition of the nicotinamide adenine dinucleotide phosphate oxidase-dependent respiratory burst. J. Immunol. 168:3458-3463. (Pubitemid 34250411)
7. Debebe Z, et al. 2011. Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets - iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol. Pharmacol. 79:185-196.
8. Fernandes SS, et al. 2010. Identification of a new hexadentate iron chelator capable of restricting the intramacrophagic growth of Mycobacterium avium. Microbes Infect. 12:287-294.
9. Heli H, Mirtorabi S, Karimian K. 2011. Advances in iron chelation: an update. Expert Opin. Ther. Pat. 21:819-856.
10. Kim CM, Shin SH. 2009. Effect of iron-chelator deferiprone on the in vitro growth of staphylococci. J. Korean Med. Sci. 24:289-295.
11. Kontoghiorghes GJ. 2011. A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients. Hemoglobin 35:301-311.
12. Lewis RE, et al. 2011. Activity of deferasirox in Mucorales: influences of species and exogenous iron. Antimicrob. Agents Chemother. 55:411-413.
13. Loyevsky M, et al. 1999. Chelation of iron within the erythrocytic Plasmodium falciparum parasite by iron chelators. Mol. Biochem. Parasitol. 101:43-59. (Pubitemid 29257840)
14. Neupane GP, Kim DM. 2010. In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus. Eur. J. Clin. Microbiol. Infect. Dis. 29:407-410.
15. Nunes A, et al. 2010. Fluorescent 3-hydroxy-4-pyridinone hexadentate iron chelators: intracellular distribution and the relevance to antimycobacterial properties J. Biol. Inorg. Chem. 15:861-877.
16. Qiu DH, Huang ZL, Zhou T, Shen C, Hider RC. 2011. In vitro inhibition of bacterial growth by iron chelators. FEMS Microbiol. Lett. 314:107-111.
17. Reyes HM, Tingle EJ, Fenves AZ, Spiegel J, Burton EC. 2008. Pulmonary invasive mucormycosis in a patient with secondary iron overload following deferoxamine therapy. Proc. (Bayl. Univ. Med. Cent.). 21:378-381.
18. Sandiumenge A, Rello J. 2012. Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management. Curr. Opin. Pulm. Med. 18:187-193.
19. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB. 2004. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46:254-263. (Pubitemid 37532833)
20. Soummer A, et al. 2008. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob. Agents Chemother. 52:1585-1586. (Pubitemid 351522044)
21. Spellberg B, et al. 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46:155-164. (Pubitemid 351269151)
22. Tam TF, et al. February 2011. Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalky1-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues. Apotex, Inc. US patent 7,893,269.
23. Tribble DR, et al. 2011. Infection-associated clinical outcomes in hospitalized medical evacuees after traumatic injury: trauma infectious disease outcome study. J. Trauma 71:S33-S42.
24. van Asbeck BS, et al. 2001. Anti-HIV effect of iron chelators: different mechanisms involved. J. Clin. Virol. 20:141-147.
25. Walcourt A, Loyevsky M, Lovejoy DB, Gordeuk VR, Richardson DR. 2004. Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites. Int. J. Biochem. Cell Biol. 36:401-407. (Pubitemid 37542439)
26. White RL, Burgess DS, Manduru M, Bosso JA. 1996. Comparison of three different in vitro methods of detecting synergy: time-kill, checker-board, and E test. Antimicrob. Agents Chemother. 40:1914-1918. (Pubitemid 26277815)
27. Zarember KA, Cruz AR, Huang CY, Gallin JI. 2009. Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus. Antimicrob. Agents Chemother. 53:2654-2656.
28. Zheng H, Gal S, Weiner LM, Bar-Am Warshawsky OA, Fridkin M, Youdim MB. 2005. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95:68-78. (Pubitemid 41384426)